Oncology · In-Market · Updated August 2026
First line is a class contest. After progression the market stops being one market and splits into mutation-defined segments that do not compete with each other.
HR+/HER2- is the largest breast cancer subtype, and systemic therapy value concentrates in the recurrent and metastatic population rather than in incidence. That population is assembled from two sources on different time horizons - patients metastatic at diagnosis, and the substantial share of early-stage cases that recur later - and a model that sizes from incidence alone will misplace both the volume and its timing.
Two different logics govern the market. In first line, endocrine therapy plus a CDK4/6 inhibitor is standard, and the class competes on survival evidence and tolerability. After progression the logic changes entirely: treatment becomes biomarker-directed, with separate agents for distinct mutations, each added to endocrine therapy. An asset entering after first line is not competing for one pool but for a single mutation-defined slice of it.
Testing is what gates that slice. Coverage of the targeted later-line agents requires companion-diagnostic-confirmed mutations, so re-testing at progression is a precondition of reimbursement rather than best practice. Patients who progress without being re-tested are unreachable by any of these agents, which makes re-biopsy and circulating-tumour-DNA testing rates the ceiling on the segment. Negotiation has now begun entering the first-line class, resetting the price reference against which later entrants are judged.
AXLRx HR+/HER2- reports size each biomarker-defined segment separately and read access through the testing pathway. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
HR+/HER2- accounts for about 68% of US breast cancers, with roughly 317,000 new invasive female cases in 2025. Around 6% are metastatic at diagnosis and 20 to 30% of early-stage cases later recur, and it is that recurrent and metastatic population where systemic therapy value concentrates. Distant-stage five-year survival is about 32%. Sizing from incidence alone will misplace the opportunity, because the treated metastatic pool is assembled from two different sources over different time horizons.
Two different logics. First-line metastatic treatment is endocrine therapy plus a CDK4/6 inhibitor, where ribociclib is differentiated by consistent overall-survival benefit, with MONALEESA-2 showing 63.9 against 51.4 months. After CDK4/6 progression the market stops being a class contest and becomes biomarker-directed: elacestrant for ESR1-mutant disease, alpelisib for PIK3CA-mutant, and capivasertib for AKT-pathway-altered disease, each added to fulvestrant. An asset entering after first line is not competing for a single pool but for one mutation-defined slice of it.
Directly. Coverage of the biomarker-targeted agents requires companion-diagnostic-confirmed mutations, so ESR1 and PIK3CA testing at progression is a precondition of reimbursement rather than a clinical nicety. A patient who progresses without being re-tested is not addressable by any of the targeted later-line options. Re-biopsy and circulating-tumour-DNA testing rates therefore set the ceiling on that segment.
Mixed, and moving. All approved oral agents route through Medicare Part D with commercial prior authorisation and step edits. Palbociclib was selected for IRA Medicare negotiation with a price cut of roughly 50% to $7,871 a month, effective 2027; other CDK4/6 class members have not yet been selected. Among the later-line agents, elacestrant's cost-effectiveness at $8.67 million per QALY sits far above the $150,000 threshold, which is a difficult starting position for any value argument built on the same basis.
A patient-flow model that separates de novo metastatic from recurrent disease and sizes each biomarker-defined later-line segment; competitive intelligence on the first-line CDK4/6 contest and the overall-survival evidence behind it; a payer and HTA read covering Part D routing, companion-diagnostic coverage requirements and the IRA exposure now entering the class; and KOL and HTA strategy work across the US and UK. Each is scoped to your asset.